Best IPOs to Watch: Top Contenders for Your Portfolio

Let's talk about spotting winners before the crowd does. Everyone wants to get in early on the next Snowflake or Airbnb, that rocket ship IPO that defines a portfolio for years. But here's the hard truth most articles won't tell you: by the time a company files its S-1 with the SEC, the easiest money has often already been made by venture capitalists and private investors. The real game isn't about reacting to headlines; it's about building a watchlist of private companies with IPO potential and understanding the market forces that will push them public.

This isn't a crystal ball gazing exercise for 2026. It's a framework. We're looking at companies that are currently shaping industries—think AI infrastructure, next-generation biotech, climate solutions—and are on a trajectory that makes a public offering in the next few years not just possible, but likely. We'll break down what makes them tick, the red flags most beginners miss, and how to think about valuation before the ticker symbol is even assigned.

In This Deep Dive

The Changing IPO Landscape: Why Timing Matters More Than Ever
Top IPO Contenders Across Key Sectors
How to Evaluate a Pre-IPO Company: A Practical Framework
Common Pitfalls and How to Avoid Them
Your IPO Strategy Questions Answered

The Changing IPO Landscape: Why Timing Matters More Than Ever

Gone are the days of companies rushing to go public at age three. The average age of a company at IPO has steadily increased, according to data from the University of Florida's IPO database. Companies are staying private longer, fueled by deep pools of private capital from sovereign wealth funds, crossover funds, and mega-VCs. This means when they do go public, they're often massive, later-stage businesses.

For you, the public market investor, this changes the game. You're not buying a scrappy startup's dream. You're often buying a scaled, growth-stage company where the risk profile is different. The upside might be more moderate, but so might the volatility. The 2021-2022 period was a wild ride—record-breaking debuts followed by brutal corrections. That hangover has made everyone more cautious.

My take? This caution is healthy. It forces the market to focus on fundamentals like a clear path to profitability and sustainable unit economics, not just top-line growth at any cost. The best upcoming IPOs will be those that can demonstrate they've weathered the shift in sentiment.

Keep an eye on the broader market indices and the performance of recent IPOs in the same sector. If the ARK Innovation ETF (ARKK) or a basket of recent tech listings is struggling, it can dampen appetite for new issues, no matter how good the company is. Sentiment is a powerful short-term force.

Top IPO Contenders Across Key Sectors

Instead of just naming names, let's look at the types of companies that have the right ingredients. I'm grouping them by theme because specific companies can get acquired or stumble, but the trends are durable.

1. AI & Machine Learning Infrastructure

Everyone's chasing the application layer, but the picks-and-shovels plays are often safer and more lucrative. Look for companies providing the essential tools, platforms, or infrastructure that enable other businesses to build AI. Think data labeling at scale, specialized cloud compute for model training, or MLOps (Machine Learning Operations) software. These businesses have recurring revenue models and serve a booming, non-cyclical demand.

A specific example that's often discussed in tech circles? A company like Scale AI (though its IPO timeline is always speculative). They've positioned themselves as the data engine for AI, working with both the government and autonomous vehicle companies. Their key metric isn't just revenue growth, but the diversity and stickiness of their enterprise contracts.

2. Climate Tech & Industrial Decarbonization

This isn't just about ESG feel-good funds anymore. The Inflation Reduction Act in the US and similar policies in Europe have unleashed a tidal wave of capital into practical climate solutions. The winners here will be companies with hard technology—things that actually reduce carbon emissions in heavy industries, agriculture, or energy storage.

I'm skeptical of many carbon accounting software plays. The moat seems thin. I'm more interested in companies developing novel battery chemistries for grid storage or creating low-carbon cement and steel. Their path to an IPO depends on successfully scaling manufacturing, which is capital-intensive and a perfect reason to tap public markets. Reports from groups like the McKinsey Global Institute consistently highlight the massive investment needed in this transition.

3. Next-Generation Biotech & Healthcare

The biotech IPO window is famously fickle, opening and closing with macroeconomic tides. However, companies that have moved beyond the pure R&D phase and have a drug in late-stage clinical trials or, even better, recently commercialized, become compelling candidates. The focus is shifting from just promising science to commercial execution.

Look for platforms, not just one-drug wonders. A company with a proprietary drug discovery engine (using AI, for instance) that can generate multiple drug candidates has a more compelling story for public investors than a bet on a single Phase II trial. The regulatory risk is more spread out.

Sector Theme	What to Look For (The "Moats")	Key Risk Factor	Potential IPO Catalyst
AI Infrastructure	Recurring enterprise revenue, high gross margins, role as an essential "picks & shovels" provider.	Intense competition from cloud giants (AWS, GCP, Azure) deciding to build similar tools in-house.	Need for large capital infusion to outpace competitors in R&D and sales.
Climate Tech	Protected IP (patents), strategic partnerships with large industrials, alignment with government subsidy programs.		Major commercial contract or reaching a key production milestone that requires expansion capital.
Biotech Platforms	Platform technology validating multiple drug candidates, experienced management with prior FDA approvals.	Clinical trial failures, changes in FDA approval pathways, patent cliffs.	Positive Phase III trial results or first drug approval, requiring capital for sales force build-out and further pipeline development.

How to Evaluate a Pre-IPO Company: A Practical Framework

When you read a glowing profile about a "hot pre-IPO company," don't just look at the valuation. Dig into these aspects, which are often hinted at in business journalism but rarely laid out plainly for individual investors.

The Leadership Test: Has the CEO or CFO ever taken a company public before? This is huge. The IPO process is a brutal, multi-month roadshow and regulatory marathon. A team that's done it before is less likely to make novice mistakes in pricing or investor communication. Check their LinkedIn profiles.

Investor Quality in Late Private Rounds: Who is funding the Series D, E, or F? If you see names like Fidelity, T. Rowe Price, or mutual funds traditionally associated with public markets, it's a strong signal. These are "crossover" investors who do deep diligence with an eye toward the public markets. Their participation is a major endorsement of the financials.

Revenue Composition: Is revenue growing, but more importantly, is it becoming more predictable? A shift from one-time project fees to annual recurring revenue (ARR) or subscription models is a green flag. It makes future cash flows more visible, which public markets love.

Here's a subtle mistake I see: people get obsessed with total addressable market (TAM) size. A $100 billion TAM is meaningless if the company can't capture at least 1-2% of it in a defensible way. Focus on market share trends within a specific niche first. Dominating a $5 billion niche is better than having 0.1% of a $500 billion one.

Common Pitfalls and How to Avoid Them

Falling for the "Story" Over Numbers: A compelling narrative about AI, blockchain, or the metaverse can be seductive. Always anchor it back to the financials in the S-1. How much cash is burning per quarter? What's the customer acquisition cost, and is it going down? If the story is all you have, walk away.

IPO Day FOMO (Fear Of Missing Out): The absolute worst time to buy is often in the first hour of trading. The price is set by a small group of institutional investors, and retail gets swept up in the frenzy. More often than not, there's a better entry point weeks or months later after the initial volatility settles. Look at the chart of almost any hyped IPO from the last five years—see that dip after the pop? That's your lesson.

Ignoring the Lock-Up Expiration: Early employees and investors are typically prohibited from selling their shares for 90 to 180 days post-IPO. When that lock-up period expires, a wave of new supply can hit the market, often depressing the price. Mark this date on your calendar. It's not always a sell signal, but it's a period of heightened pressure.

Your IPO Strategy Questions Answered

How can I, as an individual investor, get access to shares before the IPO at the offer price?

Realistically, it's very difficult. The allocation of shares at the IPO price is overwhelmingly given to large institutional clients of the underwriting investment banks. Some online brokerages like Fidelity, Charles Schwab, or Robinhood have programs that offer limited access to certain IPOs for their clients, but demand usually far exceeds supply. Don't bank on this as a primary strategy. Focus on building a well-researched watchlist and being patient for a post-IPO entry point.

What's a major red flag in an S-1 filing that most people overlook?

Go straight to the "Risk Factors" section and look for dependency. Is the company warning that a single customer represents more than 20-25% of its revenue? That's a massive concentration risk. What if that one relationship sours? Similarly, look for dependency on a single supplier or a key piece of licensed technology. Diversification matters, even for fast-growing companies. Another subtle one: excessive related-party transactions. It can suggest poor governance.

Is investing in an IPO-focused ETF or SPAC a good alternative to picking individual stocks?

It's a different approach with its own trade-offs. An ETF like the Renaissance IPO ETF (IPO) provides instant diversification across recent listings, which reduces company-specific risk. However, you also get the good with the bad and the mediocre. You're outsourcing stock selection. SPACs (Special Purpose Acquisition Companies) have a much spottier track record. While there have been successes, the 2020-2021 SPAC boom left many investors with significant losses as post-merger companies failed to deliver on projections. I generally view the SPAC route with more skepticism than a traditional IPO due to less rigorous upfront disclosure and often overly optimistic forecasts.

What metric should I prioritize when a loss-making tech company goes public?

Free cash flow margin trend. Forget just net income. If a company is investing heavily in growth (sales, marketing, R&D), it will show losses. But look at its core business profitability. Is the gross profit margin healthy and improving? More critically, is the cash it burns from operations decreasing as a percentage of revenue? This shows the underlying business model is becoming more efficient. The path to profitability is clearer when you see operating leverage kicking in, even if the bottom line is still red.